Trial Profile
A Double-blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 25 Jul 2018 Results (n=577) evalauting the totality of safety findings from 7 clinical trials (NCT00048542, NCT00775437, NCT00690573, NCT01166282, NCT01251614, NCT00409682 and NCT00686374) published in the Journal of Pediatrics
- 20 Jun 2016 Trial focus has been changed from safety to efficacy study.